Role of Frailty in Identifying Benefit From Transcatheter Versus Surgical Aortic Valve Replacement.

ABSTRACT:

Background

Frailty is associated with a higher risk for adverse outcomes after aortic valve replacement (AVR) for severe aortic valve stenosis, but whether or not frail patients derive differential benefit from transcatheter (TAVR) versus surgical (SAVR) AVR is uncertain.

Methods

We linked adults ≥65 years old in the US CoreValve HiR trial (High-Risk) or SURTAVI trial (Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients) to Medicare claims, February 2, 2011, to September 30, 2015. Two frailty measures, a deficit-based and phenotype-based frailty index (FI), were generated. The treatment effect of TAVR versus SAVR was evaluated within FI tertiles for the primary end point of death and nondeath secondary outcomes, using multivariable Cox regression

SUBMITTER: Strom JB 

PROVIDER: S-EPMC8692442 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature